Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours (Q42640096)

4 November 2017

title

Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours (English)

1 reference

4 November 2017

1 reference

Leonid Gibiansky

1

1 reference

4 November 2017

Liviawati Sutjandra

2

1 reference

4 November 2017

Sameer Doshi

3

1 reference

4 November 2017

Jenny Zheng

4

1 reference

4 November 2017

Winnie Sohn

5

1 reference

4 November 2017

Mark C Peterson

6

1 reference

4 November 2017

Graham R Jang

7

1 reference

4 November 2017

Andrew T Chow

8

1 reference

4 November 2017

Juan José Pérez-Ruixo

9

1 reference

4 November 2017

publication date

1 April 2012

1 reference

Clinical Pharmacokinetics

4 November 2017

published in

1 reference

4 November 2017

volume

51

1 reference

4 November 2017

issue

4

1 reference

4 November 2017

page(s)

247-260

1 reference

Clinical features of metastatic bone disease and risk of skeletal morbidity

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life".

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Theoretical considerations of target-mediated drug disposition models: simplifications and approximations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598090-000000000-00000

Skeletal complications of malignancy

21 January 2018

1 reference

12 December 2020

Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines

1 reference

12 December 2020

Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast

1 reference

12 December 2020

Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.

1 reference

12 December 2020

Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women

1 reference

12 December 2020

Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75

1 reference

12 December 2020

Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis

1 reference

12 December 2020

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

10.2165/11598090-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

4 November 2017

1024301545

0 references

1 reference